Abstract Body

Background

Illumina next-generation sequencing (NGS) is the benchmark for HIV drug resistance (HIVDR) monitoring. Sequencing by Oxford Nanopore Technologies (ONT) offers advantages in cost, portability, and long-read capacity, but earlier error rates raised doubts about the reliability of detected variants. This is particularly critical for minority resistant variants, which are clinically relevant in treatment failure and have been reported at frequencies between 3.9 and 19.6% in dolutegravir-experienced cohorts. We evaluated the performance of the latest ONT sequencing technology versus Illumina for HIVDR detection, including minority variants.

Methods

Twenty-one patient samples (14 plasma, 7 proviral DNA) covering protease (PR), reverse transcriptase (RT), and integrase (IN) were amplified and sequenced on both platforms from identical PCR products. Resistance-associated mutations of RT and IN were classified according to the IAS–USA drug resistance mutation list 2025. Variant calling was performed with a 2% cutoff, and concordance between platforms was assessed by frequency deviation.

Results

A total of 83 HIVDR-associated mutations were identified. All 79 mutations detected by Illumina were also identified by ONT. Additionally, ONT detected four mutations that were either below the 2% threshold or absent in Illumina: K70R (1.75% vs. 2.03%), K101R (0% vs. 4.97%), and Y181C (0% vs. 3.69%), all occurred at frequencies <5%. The mean deviation across platforms was -1.78%. Importantly, 73 of 83 mutations (88%) showed deviations <5%. Minority variants <20% were comparably identified (ONT: n=21, range 2.03–16.22%; Illumina: n=22, range 0–18.38%). Discrepancies >5% (n=10) were not attributable to sample type, genomic region, or sequencing platform.

Conclusions

The latest ONT sequencing technology overcomes previous error limitations and provides reliable detection of HIVDR-associated mutations, including minority variants. With high concordance to Illumina, ONT sequencing is suitable for routine diagnostics and large-scale surveillance, particularly in settings where cost and accessibility are critical.